Search
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedAfter the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.
Pratosartan
go.drugbank.com/drugs/DB20100ExperimentalPratosartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Pratosartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Pratosartan has a monoisotopic molecular weight of 426.22 Da.
Categories: Heterocyclic Compounds, 1-RingRipisartan
go.drugbank.com/drugs/DB20229ExperimentalRipisartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Ripisartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Ripisartan has a monoisotopic molecular weight of 426.19 Da.
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawnChymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. … [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.
Products: Chymodiactin Injection - 4 Nkat Units/2mlCYT-6091
go.drugbank.com/drugs/DB05991ExperimentalIt was under investagtion in clinical trials NCT00356980 and NCT00436410 for the treatment of various cancers. … CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold
Categories: Compounds used in a research, industrial, or household settingQuizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalcytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death. … [L47426] FLT3-ITD mutation is present in 75% of FLT3-mutated AML, leading to constitutively active FLT3 and thus poorer overall survival and higher risk of relapse.
Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)ureaCategories: P-glycoprotein inhibitors, P-glycoprotein substratesInterferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalInterferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. … The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Synonyms: IFN-G, IFN-γEtuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878] … [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system.
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnIt is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.
Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidineAnacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigational[A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717] … [L44717] Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns.
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors